UDkt Benjamin Philip Levy

UDkt. Benjamin Levy uyi-thoracic oncologist yezokwelapha ophinde asebenze njengomqondisi wemtholampilo we-oncology yezokwelapha e-Johns Hopkins Sidney Kimmel Cancer Centre esibhedlela sase-Sibley Memorial futhi njengoprofesa ohlangene we-oncology e-Johns Hopkins University School of Medicine. Usebenza eSibley Memorial Hospital eJohns Hopkins Sidney Kimmel Cancer Centre.

Dr. Levy is a clinician scientist who is interested in novel immunotherapeutic treatments for patients with advanced umdlavuza wamaphaphu, as well as biomarkers that help identify those patients who are more likely to respond to such medicines. He specialises in thoracic malignancies such as non-small cell lung cancer, small cell lung cancer, thymic malignancies, and umdlavuza wekhanda nentamo.

Dr. Levy graduated from the Medical College of Georgia. He completed an internal medicine residency at Georgetown University Hospital, followed by a hematology/oncology fellowship at New York Presbyterian/Weill Cornell Medical Centre, where he received the Department of Medicine Research Fellow of the Year Award and the 2009 American Society of Clinical Oncology Young Investigator Award for his umdlavuza wendlala clinical research. Dr. Levy previously worked as an assistant professor at the Icahn School of Medicine, as the medical director of thoracic oncology for Mount Sinai Health Systems, and as the associate director of Mount Sinai Hospital’s Cancer Izivivinyo zemitholampilo Ihhovisi.

UDkt. Levy usebenze kumakomiti amaningi e-American Society of Clinical Oncology (ASCO) futhi njengamanje ungumhleli ohlangene weKomidi leNyuvesi ye-ASCO. Usebenze ebhodini labahleli le-Journal of Clinical Oncology iminyaka emibili futhi njengamanje ungumbuyekezi wesikhashana wezincwadi ezengeziwe ezifana neClinical Lung Cancer, The Oncologist, kanye nethagethi ye-Onco. UDkt Levy usanda kukhethwa njengomunye wodokotela abayi-15 kuphela ezweni abazobamba iqhaza ohlelweni oluhlonishwayo lwe-ASCO Leadership Development, okuhloswe ngalo ukuvundulula nokuqeqesha abaholi be-ASCO bakusasa. UDkt. Levy uphinde asebenze ku-Alliance Respiratory Committee, I-IASLC Staging Committee, kanye ne-IASLC Career Development & Fellowship Committee ngaphezu kwemisebenzi yakhe ye-ASCO.

• Umdlavuza we-Lung
• immunotherapy

Becker DJ, Wisnivesky JP, Grossbard ML, Chachoua A, Camidge DR, Levy BP. "Ukusinda Kwabesifazane Base-Asia Abanomdlavuza Othuthukile Wamaphaphu Ngenkathi Ye-Tyrosine Kinase Inhibitor Therapy." I-Clin Lung Cancer. 2017 Jan;18(1):e35-e40. doi: 10.1016/j.cllc.2016.08.008.

Levy BP, Rao P, Becker DJ, Becker K. "Ukuhlasela Ithagethi Enyakazayo: Ukuqonda Ukumelana Nokulawula Inqubekelaphambili Ezigulini Zomdlavuza Wamaphaphu E-EGFR-Positive Ezelashwe Nge-Tyrosine Kinase Inhibitors." I-oncology (Williston Park). 2016 Jul;30(7):601-12. Buyekeza.

Levy BP, Chioda MD, Herndon D, Longshore JW, Mohamed M, Ou SH, Reynolds C, Singh J, Wistuba II, Bunn PA Jr, Hirsch FR. "Ukuhlolwa Kwemolekyuli Ukwelashwa Kwe-Metastatic Non-Small Cell Lung Cancer: Ungazisebenzisa Kanjani Izincomo Ezisekelwe Ebufakazini." Oncologist. 2015 Okthoba;20(10):1175-81. doi: 10.1634/theoncologist.2015-0114.

Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS . "Umsebenzi nokuphepha kwe-nivolumab, i-anti-PD-1 immune checkpoint inhibitor, yeziguli ezinomdlavuza wamaphaphu osezingeni eliphezulu, ophikisayo we-squamous non-cell-cell (CheckMate 063): isigaba 2, isilingo sengalo eyodwa." I-Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9.

Levy BP, Becker DJ. "Isikhathi sokuhlolwa kwe-tomography yedosi ephansi manje: umbono we-oncologist yezokwelapha." I-oncology (Williston Park). 2014 Nov;28(11):964-6. Akukho okungabonakali okutholakalayo.